Creative Medical Tech

Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: revenue was $0 as expected for this clinical-stage biotech, but net loss of $1.51M was slightly deeper than the $1.44M anticipated. Diluted EPS missed the ($0.39) consensus, coming in at ($0.41), largely driven by a 48% YoY surge in SG&A expenses due to nationwide marketing campaigns. While R&D expenses decreased as the CELZ-201 ADAPT trial transitioned to follow-up, the company significantly strengthened its liquidity via a $4.5B warrant inducement transaction, ending the quarter with $8.7M in cash.